All In Biotech

Drug Trial Radar · NCT03603548

Comparison of Safety and Efficacy of Two Variants of Prolonged - Released Tacrolimus (Advagraf vs. Envarsus ) in Patients After Liver Transplantation : Single Center Randomised Control Trial

Last checked: Nov 20, 2026Latest source record: Jul 27, 2018 (this record)Source: ClinicalTrials.govMethods & limitations

Status unknownPivotal-lookingRandomized with 200 participants. This is a heuristic, not a regulatory label.

Status

Status unknown

Enrollment

200

Planned (sponsor's estimate)

Start

Jul 9, 2018

Primary completion

Jul 9, 2023

Study completion Jul 9, 2023

Sponsor

Lead sponsor
Medical University of WarsawAcademic, hospital or other
Sponsor type
Academic, hospital or other
First posted
Jul 27, 2018

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Not applicable
Allocation
Randomized
Model
Single group
Masking
None
Primary purpose
Treatment
FDA-regulated drug
No
Who can join
All sexes, from 18 years, up to 70 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

Adult patients after liver transplantation initially treated with traditional Tacrolimus variant- Prograf, switched on day 10 after orthotropic liver transplantation (OLTx) on prolonged released Tacrolimus variant in 1:1 ratio ( Advagraf vs. Envarsus)

Conditions

  • Liver Transplant Rejection
  • Immunosuppression

Interventions

  • EnvarsusDrug

    Patients after liver transplantation initially treated with traditional Tacrolimus variant- Prograf, switched on day 10 after OLTx on prolonged released Tacrolimus variant in 1:1 ratio ( Advagraf vs. Envarsus)

  • AdvagrafDrug

    Patients after liver transplantation initially treated with traditional Tacrolimus variant- Prograf, switched on day 10 after OLTx on prolonged released Tacrolimus variant in 1:1 ratio ( Advagraf vs. Envarsus)

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. acute rejectionTime frame: 12 months
  2. chronic rejectionTime frame: 5 years
  3. tremorTime frame: 12 months
  4. de novo diabetesTime frame: 5 years

Locations

1 site in 1 country. Site status is shown where the registry gives one.

  • Warsaw Medical University

    Warsaw, Poland · Recruiting

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.